Exagen (XGN) to Announce Quarterly Earnings on Tuesday

Exagen (NASDAQ:XGN) is projected to announce its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $17.80 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:30 AM ET.

Exagen (NASDAQ:XGN) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.07. The business had revenue of $17.31 million during the quarter, compared to analysts’ expectations of $16.41 million. Exagen had a negative net margin of 29.49% and a negative return on equity of 94.37%. On average, analysts expect Exagen to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Exagen Stock Down 5.1%

Shares of XGN stock traded down $0.22 on Tuesday, reaching $4.18. 74,804 shares of the stock were exchanged, compared to its average volume of 399,241. The company has a current ratio of 3.47, a quick ratio of 3.47 and a debt-to-equity ratio of 1.67. The business’s 50 day moving average price is $4.52 and its 200 day moving average price is $3.88. The company has a market capitalization of $100.89 million, a price-to-earnings ratio of -4.70 and a beta of 2.02. Exagen has a twelve month low of $2.59 and a twelve month high of $12.23.

Analyst Upgrades and Downgrades

XGN has been the topic of a number of recent analyst reports. Wall Street Zen upgraded Exagen from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Canaccord Genuity Group lowered their price target on Exagen from $10.00 to $8.00 and set a “buy” rating for the company in a report on Monday, April 20th. BTIG Research dropped their price target on shares of Exagen from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Weiss Ratings cut shares of Exagen from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 12th. Finally, Roth Capital assumed coverage on shares of Exagen in a research report on Wednesday, June 24th. They set a “buy” rating and a $8.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.11.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Truvestments Capital LLC raised its holdings in shares of Exagen by 109.5% in the fourth quarter. Truvestments Capital LLC now owns 6,169 shares of the company’s stock valued at $38,000 after buying an additional 3,225 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of Exagen during the first quarter worth about $25,000. Larson Financial Group LLC purchased a new position in shares of Exagen during the third quarter worth about $105,000. Persistent Asset Partners Ltd acquired a new position in Exagen in the 4th quarter valued at about $80,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Exagen in the 4th quarter valued at about $82,000. 75.25% of the stock is owned by hedge funds and other institutional investors.

Exagen Company Profile

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.